Keywords
hyperhomocysteinemia
arterial hypertension
How to Cite
Abstract
Introduction: Chronic kidney disease (CKD) is a heterogeneous group of disorders that manifest differently with a multifactorial etiology. In addition to known factors such as diabetes, high blood pressure, genetic predisposition, age, gender, race, physical inactivity, obesity, and MIA, in recent years, high concentrations of homocysteine have also been considered as an independent risk factor in the acceleration of the progression of CKD, which, together with arterial hypertension, apparently affect the acceleration of the progress of chronic renal diseases.
Materials and Methods: In a cohort-prospective study, 100 patients were treated (40 women with an average age of 55.40±8.20 years and 60 men with an average age of 56.00±9.50 years) with CKD in the third stage (stage III and b b) with a GFR of 30- 59 ml/min/ 1.73m2 determined according to the formula modification of diet in renal disease (MDRD- GFR in ml/min for 1.73 m2=175 x Serum creatinine (Cr) -1.154 x age-0.203x1.212 (if the patient is black) x 0.742 (if female) treated in the internal medicine clinic at the Clinical Hospital in Tetovo, in the period January-2023-December-2023 randomized according to gender, age, nationality, primary kidney disease…
Results: The results obtained at the beginning of the study for all the examined parameters and those obtained after 12 months, both from the patients with Chronic disease and the control group of healthy individuals, are presented in the text below.
A significant difference was observed between the patients and the control group with p<0.0001.
Conclusion: CKD is a frequent occurrence worldwide (1 in 10 inhabitants or 10 of the world's population suffers from CKD; therefore, it is necessary to implement preventive and therapeutic measures aimed at early detection, prevention, and treatment of that disease as a conclusion of our paper, we can confirm that there is a strong connection between HHcy and high blood pressure and that together they contribute to the acceleration and progression of CKD; therefore their treatment with folate, vitamin B12, vitamin B6 should be started at an early stage of the disease to prevent the rapid progression of CKD.
References
KDIGO, Clinical practice guideline for chronic kidney disease. Public review draft March 2022.
KIDNEY INT. 2019; 96:1048–1050
Kidney Disease. Written by Web Editorial Contributors Medically Reviewed by Minech Khatri, MD. 31-August – 2022
Csaba P. Kovesdy. International Society of Nephrology. Int.Suppl. Epidemiology of chronic kidney disease: an update 2022.Apr 2022; 12(1): 7–11.
Pushpakumar S, Kundu S, Sen U. Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Curr Med Chem. 2014; 21:3662–3672.
Marija Krstevska. Tajnata na homocisteinot. ISNB 9989-2188-6-26.
Suliman ME, Lindholm B, ет ал. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. ClinChem Lab Med. 2001;39(8):734‐738.
Ye Z, Zhang Q, Li Y et al. High prevalence of hyper homocysteine and its association with target organ damage in Chinese patients with chronic kidney disease. Nutrients. 2016; 8(10): 645‐656.
Xie DI, Yuan Y, et al. (2015). Hyperhomocysteinemia predicts renal function decline: a prospective study in hypertensive adults. Sci Rep.:16268.
Finkelstein JD (1990) Methionine metabolism in mammals. J Nutr Biochem 1: 228–237.
Finkelstein JD (1996) Concluding remarks: epilogue or prologue.In: Mato JM, Caballero A (eds) Methionine metabolism: molecular mechanisms and clinical implications. CSIC, Madrid, pp 277–282
Frontiera MS, Stabler SP, Kolhouse JF, Allen RH (1994). Regulation of methionine metabolism: effects of nitrous oxide and excess dietary methionine. J Nutr Biochem 5: 28–38
Janson J J, Galarza C R, Murúa A, Quintana I, et al. Prevalence of hyperhomocysteinemia in an elderly population. Am J Hypertens 2002; 15: 394-7.
Lussier-Cacan S, Xhignesse M, Piolot A, et al. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Am J Clin Nutr. 1996; 64:587–593.
Carson NAJ, Neill DW. Metabolic abnormalities detected in a Survey of mentally backward individuals in Northern Ireland. Arch Dis Child. 1962; 37:505-13.)
Wilcken DE, Dudman NPB, Turrel PA, et al. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism. 1998; 37:697-701.
Animesh K, Mehrotra V. Trends in blood pressure with increasing plasma homocysteine levels. J Indian Acad Clin Med 2014; 15(3-4): 188–191.
Korzeniowska K, Cieslewicz A, et al. A. Homocysteine-relation to hypertension, age and smoking in patients with newly diagnosed essential hypertension. J Med Sci 2016; 84(2): 90–96.
Xie DI, Yuan Y, et al. (2015). Hyperhomocysteinemia predicts renal function decline: a prospective study in hypertensive adults. Sci Rep.:16268.;5:16268.
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012; 379:815–822.
Yakub M, Schulze KJ, Khatry SK, et al. High plasma homocysteine increases the risk of metabolic syndrome in 6 to 8-year-old children in rural Nepal. Nutrients. 2014; 6:1649–1661.
Homocysteine Studies C. Homocysteine and risk of ischemic heart disease and stroke: a meta‐analysis. JAMA. 2002; 288:2015–2022.
Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015; 14:6.
Zengchun Ye, MD, PhD, Cheng Wang, MD, et al. Prevalence of Homocysteine-Related Hypertension in Patients with Chronic Kidney Disease.J Clin Hypertens (Greenwich). 2017 Feb; 19(2): 151–160
Brzezińska A., Balińska M.: Rola homocysteiny w procesie roz-woju zmian miażdżycowych na poziomie komórkowym. PostępyBiol. Kom., 2000; 27: 81–96.
Tsai J.C., Kuo H.T., Chiu Y.W., Hwang S.J., et al. Correlation of plasma homocysteine level with arterial stiffness and pulse pressure in hemodialysis patients. Atherosclerosis, 2005; 182: 121–1271].
Baszczuk A., Kopczyński Z., Thielmann A.: Endothelial dysfunction in patients with primary hypertension and hyperhomocysteinemia. Postępy Hig. Med. Dośw., 2014; 68: 91–100
Pushpakumar S, Kundu S, Sen U. Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Curr Med Chem. 2014; 21:3662–3672.
Yi F, Li PL. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am J Nephrol. (2008) 28:254–64. 10.1159/000110876.
Herrmann W, Obeid R. Homocysteine: A biomarker in neurodegenerative diseases. Clin Chem Lab Med. (2011) 49:435–41. 10.1515/CCLM.2011.084
Yi F, Zhang AY, Li N, Muh RW, Fillet M, Renert AF, et al. Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int. (2006) 70:88–96. 10.1038/sj.ki.5001517.
Jacobsen DW. Hyperhomocysteinemia and oxidative stress: Time for a reality check? Arterioscler Thromb Vasc Biol. (2000) 20:1182–4. 10.1161/01.ATV.20.5.1182.
Sipkens JA, Hahn N, van den Brand CS, Meischl C, Cillessen SA, Smith DE, et al. Homocysteine-induced apoptosis in endothelial cells coincides with nuclear NOX2 and nuclear NOX4 activity. Cell Biochem Biophys. (2013) 67:341–52. 10.1007/s12013-011-9297-y.
Ostrakhovitch EA, Tabibzadeh S. Homocysteine in chronic kidney disease. Adv Clin Chem. (2015) 72:77–106. 10.1016/bs.acc.2015.07.002.
Hasan Ikram, Syed Raza Jaffar, et al. Association of Hypertension with Raised Serum Homocysteine Levels. Pak Armed Forces Med J 2022; 72(3): 1125–1129.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.